Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PF-07284890 |
Synonyms | |
Therapy Description |
PF-07284890 inhibits BRAF, potentially leading to inhibition of tumor growth and tumor regression (Cancer Res 2021;81(13_Suppl):Abstract nr 1473). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PF-07284890 | PF07284890|PF 07284890|ARRY-461|ARRY461|ARRY 461 | BRAF Inhibitor 25 | PF-07284890 inhibits BRAF, potentially leading to inhibition of tumor growth and tumor regression (Cancer Res 2021;81(13_Suppl):Abstract nr 1473). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E | melanoma | predicted - sensitive | PF-07284890 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, PF-07284890 treatment led to inhibition of tumor growth, tumor regression, and survival benefit in an intracranial model, and tumor growth inhibition in a subcutaneous cell line xenograft model of melanoma harboring BRAF V600E (Cancer Res 2021;81(13_Suppl):Abstract nr 1473). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04543188 | Phase I | Binimetinib + Midazolam + PF-07284890 Binimetinib + PF-07284890 PF-07284890 | A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement | Terminated | USA | ISR | CAN | 0 |